MarketCap
Facebook
X
Telegram
Merrimack Pharmaceuticals EBITDA | MACK
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Merrimack Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.04 M | -1.73 M | -2.47 M | -2.87 M | -20.1 M | -61.5 M | -90.5 M | -142 M | -142 M | -27.3 M | -118 M | -89.1 M | -76.3 M | -45.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.73 M | -142 M | -58.7 M |
Quarterly EBITDA Merrimack Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -669 K | - | -531 K | -569 K | -447 K | - | -504 K | -486 K | -132 K | - | -525 K | -778 K | -696 K | - | 1.22 M | 1.04 M | 1.42 M | - | 1.38 M | -7.03 M | -8.82 M | - | -13.5 M | -14.9 M | -16.1 M | - | -14.2 M | -32.5 M | -26.1 M | - | -18.7 M | -26.8 M | -28.6 M | - | -34 M | -16.5 M | -29 M | - | -20.9 M | -11.7 M | -22.6 M | - | -34 M | -27.8 M | -26.6 M | - | -20.8 M | -18.1 M | -22.7 M | - | -14.6 M | -26.8 M | -13.3 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.42 M | -34 M | -13.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
TG Therapeutics
TGTX
|
123 M | $ 64.27 | 1.4 % | $ 9.28 B |  USA |
 |
Aphria Inc.
APHA
|
-8.68 M | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-6.22 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-70.5 M | - | -6.00 % | $ 238 M | USA |
 |
Trevi Therapeutics
TRVI
|
-49.2 M | $ 14.92 | -2.55 % | $ 2.01 B | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-43.3 M | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
17.2 M | - | 0.38 % | $ 12.9 M |  Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
-26.4 T | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-45.6 M | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-121 M | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-5.28 M | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-111 M | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-2.8 M | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
-39 M | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-101 M | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
-85.6 M | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
1.05 B | $ 972.42 | 1.05 % | $ 59.6 B |  Niderland |
 |
XBiotech
XBIT
|
-54 M | $ 1.97 | 3.2 % | $ 60.1 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
-6.22 M | - | -2.54 % | $ 57.2 M | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-127 M | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
-603 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
22.8 M | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-37.4 M | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-2.83 M | $ 1.76 | -2.09 % | $ 2.99 M | USA |
 |
Viridian Therapeutics
VRDN
|
-363 M | $ 30.86 | 2.22 % | $ 3.14 B | USA |
 |
Translate Bio, Inc.
TBIO
|
2.53 M | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-60.9 M | - | - | $ 1.94 B | Canada |
 |
Urovant Sciences Ltd.
UROV
|
-143 M | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-133 M | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-1.05 B | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-224 M | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
399 K | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-79.2 M | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-371 M | $ 41.4 | 2.35 % | $ 3.28 B | Canada |
 |
Leap Therapeutics
LPTX
|
-41.1 M | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-212 M | $ 31.45 | 2.08 % | $ 1.62 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
199 M | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Cortexyme
CRTX
|
-57.9 M | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.66 | -1.35 % | $ 802 M | Britain |
 |
Daré Bioscience
DARE
|
-11.9 M | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
-135 M | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-19.4 M | $ 16.05 | -2.85 % | $ 217 M | USA |
 |
Halozyme Therapeutics
HALO
|
480 M | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
-25.9 M | $ 15.34 | 0.1 % | $ 13.2 B | China |
 |
Aptorum Group Limited
APM
|
255 K | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-34.6 M | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
-216 M | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-90.4 M | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-15.3 M | - | 5743.5 % | $ 69.7 M | Canada |